Clinical Trials
16 trialsNCT07003295 2026-06-03
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06504199 2026-05-13
ZGR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Active not recruiting
NCT07261163 2026-05-13
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03863184 2026-04-28
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06252675 2026-04-20
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco
Phase 2 Recruiting
NCT06192888 2026-03-27
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT05861050 2026-02-19
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Recruiting
NCT06558604 2026-02-11
GLOASIS
The Lymphoma Academic Research Organisation
Phase 2 Recruiting
NCT04883437 2026-02-09
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
Phase 2 Recruiting
NCT06357676 2026-01-30
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT02896582 2026-01-14
LyMa101
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT06054776 2026-01-05
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT03872180 2025-08-06
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Emory University
Phase 2 Active not recruiting
NCT02558816 2025-07-24
OAsIs
Nantes University Hospital
Phase 1/2 Completed